60 Degrees Pharmaceuticals, INC 10-Q quarterly reports

60 Degrees Pharmaceuticals reported increased product revenue in Q2 2026, but also a significant rise in operating expenses and net loss, with substantial doubt cast on its ability to continue as a going concern.

60 Degrees Pharmaceuticals reported a slight decrease in product revenue for Q1 2026, alongside increased operating expenses, while continuing to focus on its infectious disease pipeline and managing its cash position.

60 Degrees Pharmaceuticals, Inc. reported increased product and research revenues for Q3 2025, but continued to incur significant net losses and raised substantial capital to address ongoing going concern doubts.

60 Degrees Pharmaceuticals reports a significantly reduced net loss and surging research revenue in Q2 2025, driven by new contracts, despite a decline in product sales and ongoing 'going concern' doubts.

60 Degrees Pharmaceuticals reports increased product and research revenues for Q1 2025, but ongoing losses raise substantial doubt about its ability to continue as a going concern.

60 Degrees Pharmaceuticals saw a significant increase in product revenue and advanced its babesiosis clinical trials during the third quarter of 2024, while also addressing past financial challenges.

60 Degrees Pharmaceuticals saw a significant increase in product revenue and advanced its babesiosis clinical trial during the second quarter of 2024, while also addressing going concern issues.

60 Degrees Pharmaceuticals saw a significant increase in product revenue and a net income for the first quarter of 2024, driven by growth in commercial sales and a change in the fair value of derivative liabilities.